IP Library Granted Patent US 12,290,307
Granted Patent B2
US 12,290,307 · App. 17/325,814 · Granted May 6, 2025

Catheter ultrasound ablation

Inventors: Ran Sela (Ramat Hasharon, IL); Yuri Megel (Haifa, IL); Shimon Eckhouse (Haifa, IL)
Assignee: HEALIUM MEDICAL LTD
A61B18/1492A61B2018/00029A61B2018/00267A61B2018/00375A61B2018/00577A61B2018/00702A61B2018/00791A61B2018/00982A61B2018/00994
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,290,307
App. No.
17/325,814
Granted
May 6, 2025
Kind
B2
Abstract

Apparatus and methods are described including positioning an ultrasound transducer at a blood vessel ostium, rotating the transducer about its axis and scanning tissue of the blood vessel ostium, recording one or more baseline returned signals from the tissue, and creating a baseline image of the blood vessel ostium based on at least one of the returned signals. Tissue of the blood vessel ostium is ablated in consecutive segments by rotating the transducer segmentally until full rotation is completed. The returned signals of the ablated segments are recorded in real-time and a real-time image is created based on the one or more returned signals. Ablation is terminated after changes in the real-time returned signals and/or real-time image with respect to the baseline returned signals and/or baseline image indicate an achieved predetermined level of ablation lesion formation. Other applications are also described.

Claims (19)

1. A method for ablating an ostium of a blood vessel of a subject that extends from a chamber of a heart of the subject, the method comprising:

positioning an ultrasound transducer at the blood vessel ostium that extends from the chamber of the heart;

rotating the transducer about its axis and scanning tissue of the blood vessel ostium;

recording one or more baseline returned signals from the tissue and creating a baseline image of the blood vessel ostium based on at least one of the returned signals;

ablating tissue of the blood vessel ostium in consecutive segments by rotating the transducer segmentally until full rotation is completed;

recording the returned signals of the ablated segments in real-time with respect to the ablation of the ablated segments, and creating a real-time image based on the one or more returned signals;

comparing the real-time returned signals or the real-time image to the baseline returned signals image;

identifying changes in the real-time returned signals or real-time image with respect to the baseline returned signals or baseline image that represent changes in the tissue that correspond to ablation lesion formation; and

terminating ablation after the identified changes indicate an achieved predetermined level of ablation lesion formation.

2. The method according to claim 1 , wherein the ultrasound transducer includes at least one scanning ultrasound piezoelectric element and at least one ablating ultrasound piezoelectric element, and wherein scanning the tissue comprises scanning the tissue using the at least one scanning ultrasound piezoelectric element, and ablating the tissue comprises ablating the tissue using the at least one ablating ultrasound piezoelectric element.

3. The method according to claim 1 , wherein the ultrasound transducer includes at least two ablating ultrasound piezoelectric elements, and wherein ablating the tissue comprises ablating the tissue using the at least two ablating ultrasound piezoelectric elements.

4. The method according to claim 1 , wherein ablating tissue of the blood vessel ostium comprises creating two circumferential ring-lesions.

5. The method according to claim 1 , wherein the blood vessel includes a pulmonary vein, and the chamber of the heart includes a left atrium and wherein the method is for use with the pulmonary vein that extends from the left atrium.

6. A method comprising:

advancing into an atrium of a heart of a subject:

a catheter ultrasound transducer including one or more piezoelectric elements of which at least one piezoelectric element is an ablative piezoelectric element and at least one piezoelectric elements is an imaging piezoelectric element, and

an expandable positioner positioned in contact with walls of a pulmonary vein ostium, and enveloping at least a portion of the catheter ultrasound transducer and being configured to allow the catheter ultrasound transducer to rotate and axially translate back and forth within the expandable positioner; and

activating the catheter ultrasound transducer to image tissue at the pulmonary vein ostium of the subject by using the imaging piezoelectric element.

7. The method according to claim 6 , further comprising activating the catheter ultrasound transducer to ablate tissue at the pulmonary vein ostium of the subject by using the ablative piezoelectric element.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 20, 2021
From: SELA, RAN; MEGEL, YURI; ECKHOUSE, SHIMON
To: HEALIUM MEDICAL LTD.
Reel/Frame 056303/0760 →
Continuity (3)
Continuation 17260458
Provisional Application 62720995 · Aug 22, 2018
Related Publication 20210267680A1 · Sep 2, 2021
References Cited (113)
US 5115814A · Griffith et al. · 1992 [cited by applicant]
US 5716321A · Kerin et al. · 1998 [cited by applicant]
US 5762066A · Law et al. · 1998 [cited by applicant]
US 5817021A · Reichenberger · 1998 [cited by applicant]
US 6064902A · Haissaguerre et al. · 2000 [cited by applicant]
US 7435248B2 · Taimisto · 2008 [cited by examiner]
US 8414508B2 · Thapliyal et al. · 2013 [cited by applicant]
US 8585601B2 · Sverdlik et al. · 2013 [cited by applicant]
US 8696581B2 · Sverdlik et al. · 2014 [cited by applicant]
US 9033885B2 · Thapliyal et al. · 2015 [cited by applicant]
US 9155588B2 · Thapliyal et al. · 2015 [cited by applicant]
US 9566456B2 · Sverdlik et al. · 2017 [cited by applicant]
US 9737325B2 · Thapliyal et al. · 2017 [cited by applicant]
US 9833641B2 · Thapliyal et al. · 2017 [cited by applicant]
US 9867556B2 · Balachandran et al. · 2018 [cited by applicant]
US 9907983B2 · Thapliyal et al. · 2018 [cited by applicant]
US D814502S · Piazza et al. · 2018 [cited by applicant]
US 9955946B2 · Miller et al. · 2018 [cited by applicant]
US 9993666B2 · Tsoref et al. · 2018 [cited by applicant]
US 10286231B2 · Pederson et al. · 2019 [cited by applicant]
US 10349966B2 · Thapliyal et al. · 2019 [cited by applicant]
US 10368891B2 · Thapliyal et al. · 2019 [cited by applicant]
US 10549128B2 · Phillips et al. · 2020 [cited by applicant]
US 20010014819A1 · Ingle et al. · 2001 [cited by applicant]
US 20030009125A1 · Nita et al. · 2003 [cited by applicant]
US 20030216721A1 · Diederich et al. · 2003 [cited by applicant]
US 20040176757A1 · Sinelnikov et al. · 2004 [cited by applicant]
US 20050124897A1 · Chopra · 2005 [cited by applicant]
US 20060084966A1 · Maguire et al. · 2006 [cited by applicant]
US 20060224090A1 · Ostrovsky et al. · 2006 [cited by applicant]
US 20070265609A1 · Thapliyal et al. · 2007 [cited by applicant]
US 20080045842A1 · Furnish · 2008 [cited by applicant]
US 20080312536A1 · Dala-Krishna · 2008 [cited by applicant]
US 20090318003A1 · Hossack et al. · 2009 [cited by applicant]
US 20100049099A1 · Thapliyal et al. · 2010 [cited by applicant]
US 20100113906A1 · Marple et al. · 2010 [cited by applicant]
US 20100168570A1 · Sliwa et al. · 2010 [cited by applicant]
US 20100331658A1 · Kim et al. · 2010 [cited by applicant]
US 20110201973A1 · Stephens et al. · 2011 [cited by applicant]
US 20110257563A1 · Thapliyal et al. · 2011 [cited by applicant]
US 20110301508A1 · Sethuraman et al. · 2011 [cited by applicant]
US 20120035473A1 · Sanghvi et al. · 2012 [cited by applicant]
US 20120095335A1 · Sverdlik et al. · 2012 [cited by applicant]
US 20120123411A1 · Ibrahim et al. · 2012 [cited by applicant]
US 20120232436A1 · Warnking · 2012 [cited by applicant]
US 20140005706A1 · Gelfand · 2014 [cited by examiner]
US 20140046313A1 · Pederson et al. · 2014 [cited by applicant]
US 20140081301A1 · Tran et al. · 2014 [cited by applicant]
US 20140088630A1 · Tran et al. · 2014 [cited by applicant]
US 20140163360A1 · Stevens-wright et al. · 2014 [cited by applicant]
US 20140163372A1 · Deladi et al. · 2014 [cited by applicant]
US 20140276759A1 · Kim et al. · 2014 [cited by applicant]
US 20150011987A1 · Kobayashi et al. · 2015 [cited by applicant]
US 20150105715A1 · Pikus et al. · 2015 [cited by applicant]
US 20150257779A1 · Sinelnikov et al. · 2015 [cited by applicant]
US 20160016016A1 · Taylor et al. · 2016 [cited by applicant]
US 20160113699A1 · Sverdlik et al. · 2016 [cited by applicant]
US 20160287912A1 · Warnking · 2016 [cited by applicant]
US 20160317843A9 · Arenson et al. · 2016 [cited by applicant]
US 20170014153A1 · To et al. · 2017 [cited by applicant]
US 20170056057A1 · Thapliyal et al. · 2017 [cited by applicant]
US 20170065339A1 · Mickelsen · 2017 [cited by applicant]
US 20170354395A1 · Lupotti et al. · 2017 [cited by applicant]
US 20170354461A1 · Rothman et al. · 2017 [cited by applicant]
US 20180199911A1 · Harks et al. · 2018 [cited by applicant]
US 20180235572A1 · Moore · 2018 [cited by examiner]
US 20180303545A1 · Lupotti · 2018 [cited by examiner]
US 20180345046A1 · Gallup · 2018 [cited by applicant]
US 20190216540A1 · Melsky et al. · 2019 [cited by applicant]
US 20200093505A1 · Sinelnikov et al. · 2020 [cited by applicant]
US 20200114176A1 · Phillips et al. · 2020 [cited by applicant]
CA 2836653A1 · 2012 [cited by applicant]
EP 1009303B1 · 2009 [cited by applicant]
EP 2629683B1 · 2015 [cited by applicant]
JP H07227394A · 1995 [cited by applicant]
JP H08508432A · 1996 [cited by applicant]
JP 2001514921A · 2001 [cited by applicant]
JP 2014518717A · 2014 [cited by applicant]
WO 0182778A2 · 2001 [cited by applicant]
WO 2012120495A2 · 2012 [cited by applicant]
WO 2014022777A1 · 2014 [cited by applicant]
WO WO2014036463A1 · 2014 [cited by examiner]
WO 2017074726A1 · 2017 [cited by applicant]
WO 2020039442A1 · 2020 [cited by applicant]
WO 2022180511A1 · 2022 [cited by applicant]
International Search Report and Written Opinion from International Application No. PCT/IL2019/050941 mailed Nov. 25, 2019. [cited by applicant]
U.S. Appl. No. 17/260,458, filed Jan. 14, 2021. [cited by applicant]
U.S. Appl. No. 62/720,995, filed Aug. 22, 2018. [cited by applicant]
Lewalter, et al., “An update and current expert opinions on percutaneous left atrial appendage occlusion for stroke prevention in atrial fibrullation”, Europe Society of Cardiology, 15, 2013, pp. 652-656. [cited by applicant]
Extended European Search Report for European Application No. 19852790.5 mailed Aug. 30, 2021. [cited by applicant]
Issue Notification for U.S. Appl. No. 17/260,458 mailed Oct. 25, 2023. [cited by applicant]
Restriction Requirement for U.S. Appl. No. 17/325,362 mailed Sep. 7, 2023. [cited by applicant]
U.S. Appl. No. 63/153,477, filed Feb. 25, 2021. [cited by applicant]
International Search Report and Written Opinion from International Application No. PCT/IB2021/055422 mailed Nov. 15, 2021. [cited by applicant]
Invitation to Pay Additional Fees for International Application No. PCT/IB2021/055422 mailed Sep. 23, 2021. [cited by applicant]
International Search Report and Written Opinion from International Application No. PCT/IB2022/051547 mailed Jul. 18, 2022. [cited by applicant]
Invitation to Pay Additional Fees for International Application No. PCT/IB2022/051547 mailed May 27, 2022. [cited by applicant]
U.S. Appl. No. 63/043,832, filed Jun. 25, 2020. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/260,458 mailed Jul. 13, 2023. [cited by applicant]
Office Action for Canadian Application No. 3,105,282 mailed Mar. 6, 2023. [cited by applicant]
Office Action for Japanese Application No. 202134843 mailed Jun. 26, 2023. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/325,362 mailed Jan. 18, 2024. [cited by applicant]
Office Action for Canadian Application No. 3,105,282 mailed Dec. 8, 2023. [cited by applicant]
Office Action for Chinese Application No. 201980055189.5 mailed Oct. 28, 2023. [cited by applicant]
Office Action for Japanese Application No. 202134843 mailed Dec. 18, 2023. [cited by applicant]
Office Action for Japanese Application No. 2021-500965 mailed Mar. 29, 2024. [cited by applicant]
Corrected Notice of Allowance for U.S. Appl. No. 17/325,362 mailed Dec. 9, 2024. [cited by applicant]
Final Office Action for U.S. Appl. No. 17/325,362 mailed Jul. 5, 2024. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/IB2024/054483 mailed Sep. 25, 2024. [cited by applicant]
Invitation to Pay Additional Fees for International Application No. PCT/IB2024/054483 mailed Aug. 26, 2024. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/325,362 mailed Nov. 18, 2024. [cited by applicant]
Office Action for Canadian Application No. 3, 105,282 mailed Nov. 15, 2024. [cited by applicant]
Office Action for European Application No. 19852790.5 mailed Oct. 23, 2024. [cited by applicant]